Physician profile
Jack A Peterson
NPI 1790717163
$2,970.50
in general payments reported to CMS, 2019-2025
16 companies · $518 in 2025
The $518 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $129 · 2021: $680 · 2022: $566 · 2023: $349 · 2024: $430 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,296.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $954.30 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $589.32 | 2019-2025 | Repatha, Evenity, Otezla |
| Glaxosmithkline, LLC. | $226.67 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $217.72 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $179.94 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $156.76 | 2019-2024 | Airsupra |
| Exact Sciences Corporation | $134.18 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $131.64 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.32 | 2021-2023 | Jardiance, Synjardy |
| Novartis Pharmaceuticals Corporation | $60.64 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.18 | 2021-2022 | |
| Abbott Laboratories | $33.77 | 2023-2025 | Freestyle Libre 3, Proclaim |
| Biogen, INC. | $31.98 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $30.60 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $24.57 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $20.91 | 2023 | Hetlioz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.